Search

Douglas M. Willis

Examiner (ID: 5249, Phone: (571)270-5757 , Office: P/1624 )

Most Active Art Unit
1624
Art Unit(s)
1624
Total Applications
2485
Issued Applications
1796
Pending Applications
148
Abandoned Applications
577

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 19403572 [patent_doc_number] => 20240287083 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => SOLUTION REFLUX PROCESS FOR MAKING SUBSTITUTED IMIDAZO PYRAZOLES [patent_app_type] => utility [patent_app_number] => 18/624178 [patent_app_country] => US [patent_app_date] => 2024-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10968 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18624178 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/624178
Process for preparing substituted imidazo[4,5-c]pyrazoles Apr 1, 2024 Issued
Array ( [id] => 20578420 [patent_doc_number] => 12570662 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-10 [patent_title] => Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases [patent_app_type] => utility [patent_app_number] => 18/623738 [patent_app_country] => US [patent_app_date] => 2024-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 62815 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 114 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18623738 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/623738
Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases Mar 31, 2024 Issued
Array ( [id] => 19479390 [patent_doc_number] => 20240327432 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-03 [patent_title] => THIOPHENE-PHENOTHIAZINE COMPOUNDS AND SYNTHESIS METHOD THEREOF, AS WELL AS APPLICATION THEREOF IN PREPARATION OF PHOTOTHERAPY MEDICINES [patent_app_type] => utility [patent_app_number] => 18/623007 [patent_app_country] => US [patent_app_date] => 2024-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6532 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 199 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18623007 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/623007
THIOPHENE-PHENOTHIAZINE COMPOUNDS AND SYNTHESIS METHOD THEREOF, AS WELL AS APPLICATION THEREOF IN PREPARATION OF PHOTOTHERAPY MEDICINES Mar 30, 2024 Pending
Array ( [id] => 20277538 [patent_doc_number] => 20250302780 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-10-02 [patent_title] => METHOD OF TREATING PREMATURE EJACULATION IN HUMAN MALES WITHOUT SYMPTOMS OF BENIGN PROSTATIC HYPERTROPHY (BPH) USING TAMSULOSIN 0.2MG QOD WHICH DELAYS EJACULATION BY REDUCING THE RATE OF SECRETION AND TRANSPORT BY SEMINAL VESICLES AND PROSTATE IN THE GENITOURINARY TRACT [patent_app_type] => utility [patent_app_number] => 18/621112 [patent_app_country] => US [patent_app_date] => 2024-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 0 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18621112 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/621112
METHOD OF TREATING PREMATURE EJACULATION IN HUMAN MALES WITHOUT SYMPTOMS OF BENIGN PROSTATIC HYPERTROPHY (BPH) USING TAMSULOSIN 0.2MG QOD WHICH DELAYS EJACULATION BY REDUCING THE RATE OF SECRETION AND TRANSPORT BY SEMINAL VESICLES AND PROSTATE IN THE GENITOURINARY TRACT Mar 28, 2024 Pending
Array ( [id] => 20433249 [patent_doc_number] => 12503474 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-23 [patent_title] => Substituted pyrrolo[1,2-b]pyridazines as anthelmintics [patent_app_type] => utility [patent_app_number] => 18/622428 [patent_app_country] => US [patent_app_date] => 2024-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39515 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18622428 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/622428
Substituted pyrrolo[1,2-b]pyridazines as anthelmintics Mar 28, 2024 Issued
Array ( [id] => 20527262 [patent_doc_number] => 12545686 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-02-10 [patent_title] => Polymorphic forms of (s)-n-(3-bromo-2-fluorophenyl)-7-((4-methylpiperazin-1-yl)methyl)-7,8-dihydro-[1,4]dioxino[2,3-g]quinazolin-4-amine as EGFR inhibitors [patent_app_type] => utility [patent_app_number] => 18/614458 [patent_app_country] => US [patent_app_date] => 2024-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 11324 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18614458 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/614458
Polymorphic forms of (s)-n-(3-bromo-2-fluorophenyl)-7-((4-methylpiperazin-1-yl)methyl)-7,8-dihydro-[1,4]dioxino[2,3-g]quinazolin-4-amine as EGFR inhibitors Mar 21, 2024 Issued
Array ( [id] => 19528116 [patent_doc_number] => 20240352018 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-24 [patent_title] => SUBSTITUTED IMIDAZO[1,2-a]QUINAZOLINES AND IMIDAZO[1,2-a]PYRIDO[4,3-e]PYRIMIDINES AS INHIBITORS OF PARG [patent_app_type] => utility [patent_app_number] => 18/441757 [patent_app_country] => US [patent_app_date] => 2024-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25026 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18441757 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/441757
Substituted imidazo[1,2-A]quinazolines as inhibitors of PARG Feb 13, 2024 Issued
Array ( [id] => 19360761 [patent_doc_number] => 20240262795 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-08 [patent_title] => PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 [patent_app_type] => utility [patent_app_number] => 18/440293 [patent_app_country] => US [patent_app_date] => 2024-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 85964 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18440293 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/440293
PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 Feb 12, 2024 Pending
Array ( [id] => 19512045 [patent_doc_number] => 20240343731 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-17 [patent_title] => CRYSTALLINE FORMS OF AN IRREVERSIBLE INHIBITOR OF MENIN-MLL INTERACTION [patent_app_type] => utility [patent_app_number] => 18/437153 [patent_app_country] => US [patent_app_date] => 2024-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45853 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18437153 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/437153
CRYSTALLINE FORMS OF AN IRREVERSIBLE INHIBITOR OF MENIN-MLL INTERACTION Feb 7, 2024 Abandoned
Array ( [id] => 19638056 [patent_doc_number] => 12168656 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-12-17 [patent_title] => Process for making (e)-7-(4-((5-((2-chlorobenzylidene)amino)-2-thioxo-1,3,4-thiadiazol-3(2H)-yl)methyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid [patent_app_type] => utility [patent_app_number] => 18/434620 [patent_app_country] => US [patent_app_date] => 2024-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3778 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 118 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18434620 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/434620
Process for making (e)-7-(4-((5-((2-chlorobenzylidene)amino)-2-thioxo-1,3,4-thiadiazol-3(2H)-yl)methyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid Feb 5, 2024 Issued
Array ( [id] => 19432452 [patent_doc_number] => 20240300950 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => CRYSTALLINE FORMS OF N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-d]PYRIMIDIN-6-YL][PHENYL]-4-[[3(R)-[(1-OXO-2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL[METHYL]-2-PYRIDINECARBOXAMIDE AS A COVALENT INHIBITOR OF MENIN-MLL INTERACTION [patent_app_type] => utility [patent_app_number] => 18/427226 [patent_app_country] => US [patent_app_date] => 2024-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49582 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18427226 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/427226
Crystalline forms of N[4[4-(4-Morpholinyl)-7H-Pyrrolo[2-3-D]Pyrimidin-6-yl]Phenyl]-4-[[3(R)-[(1-Oxo-2-Protein-1-yl)Amino]-1-Piperidinyl]Methyl]2-Pyridinecarboxamide] Jan 29, 2024 Issued
Array ( [id] => 19345165 [patent_doc_number] => 20240254128 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-01 [patent_title] => SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS [patent_app_type] => utility [patent_app_number] => 18/423972 [patent_app_country] => US [patent_app_date] => 2024-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38174 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18423972 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/423972
SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS Jan 25, 2024 Abandoned
Array ( [id] => 20120438 [patent_doc_number] => 20250235469 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-07-24 [patent_title] => Synergistic combinations of Finasteride, Dutasteride, and Minoxidil [patent_app_type] => utility [patent_app_number] => 18/421107 [patent_app_country] => US [patent_app_date] => 2024-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 0 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18421107 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/421107
Synergistic combinations of Finasteride, Dutasteride, and Minoxidil Jan 23, 2024 Pending
Array ( [id] => 20270795 [patent_doc_number] => 12440560 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-14 [patent_title] => Substituted pyrimidines as vaccine adjuvants [patent_app_type] => utility [patent_app_number] => 18/420017 [patent_app_country] => US [patent_app_date] => 2024-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 8004 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18420017 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/420017
Substituted pyrimidines as vaccine adjuvants Jan 22, 2024 Issued
Array ( [id] => 19528126 [patent_doc_number] => 20240352028 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-24 [patent_title] => SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C [patent_app_type] => utility [patent_app_number] => 18/416739 [patent_app_country] => US [patent_app_date] => 2024-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57093 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18416739 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/416739
SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C Jan 17, 2024 Pending
Array ( [id] => 20341865 [patent_doc_number] => 12465580 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-11 [patent_title] => Substituted fatty acids for treating non-alcoholic steatohepatitis [patent_app_type] => utility [patent_app_number] => 18/414988 [patent_app_country] => US [patent_app_date] => 2024-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 6 [patent_no_of_words] => 6159 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 151 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18414988 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/414988
Substituted fatty acids for treating non-alcoholic steatohepatitis Jan 16, 2024 Issued
Array ( [id] => 19418357 [patent_doc_number] => 20240294480 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-05 [patent_title] => COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO [patent_app_type] => utility [patent_app_number] => 18/414456 [patent_app_country] => US [patent_app_date] => 2024-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33536 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 336 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18414456 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/414456
COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO Jan 15, 2024 Abandoned
Array ( [id] => 19521068 [patent_doc_number] => 12122775 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-10-22 [patent_title] => Substituted pyrido[4,3-e]pyrrolo[1,2-a]pyrazines as CK2 inhibitors [patent_app_type] => utility [patent_app_number] => 18/413246 [patent_app_country] => US [patent_app_date] => 2024-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9215 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18413246 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/413246
Substituted pyrido[4,3-e]pyrrolo[1,2-a]pyrazines as CK2 inhibitors Jan 15, 2024 Issued
Array ( [id] => 19631060 [patent_doc_number] => 20240409509 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-12 [patent_title] => COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES [patent_app_type] => utility [patent_app_number] => 18/413817 [patent_app_country] => US [patent_app_date] => 2024-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32651 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18413817 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/413817
COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES Jan 15, 2024 Pending
Array ( [id] => 19637411 [patent_doc_number] => 12168007 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-12-17 [patent_title] => Substituted piperazines as dopamine D3/D2 receptor modulators [patent_app_type] => utility [patent_app_number] => 18/409478 [patent_app_country] => US [patent_app_date] => 2024-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8538 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18409478 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/409478
Substituted piperazines as dopamine D3/D2 receptor modulators Jan 9, 2024 Issued
Menu